CS
CSTL.US Castle Biosciences Inc
- Market cap
- USD 1.04B
- P/E
- -
- P/B
- 2.22x
- ROE
- -5.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CSTL.US undervalued?
Graham numberThe Graham number of Castle Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Castle Biosciences Inc fundamental analysis
No fundamental analysis for Castle Biosciences Inc yet.
Castle Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification…
Full company profileCastle Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Castle Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 13.8M | 22.8M | 51.9M | 62.6M | 94.1M | 137M | 220M | 332M | 344M | 387M |
| Gross Profit | 8.83M | 17.5M | 44.6M | 53.0M | 78.3M | 105M | 175M | 272M | 273M | 296M |
| Operating Income | -10.9M | -3.84M | 7.33M | -6.54M | -40.1M | -72.9M | -68.0M | 8.67M | -42.8M | -32.3M |
| EBITDA | -10.4M | -3.76M | 10.3M | -7.09M | -36.6M | -58.3M | -45.0M | 38.1M | 11.3M | -9.60M |
| Net Income | -12.4M | -6.37M | 5.28M | -10.3M | -31.3M | -67.1M | -57.5M | 18.2M | -24.2M | -27.6M |
| EPS | -1.26 | -0.60 | 0.61 | -0.54 | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 | -0.90 |
| Balance Sheet | ||||||||||
| Total Assets | 9.82M | 22.4M | 120M | 439M | 463M | 447M | 453M | 531M | 579M | 579M |
| Total Liabilities | 24.1M | 32.5M | 34.6M | 23.6M | 50.8M | 48.2M | 62.1M | 75.4M | 108M | 101M |
| Shareholders' Equity | -14.3M | -10.1M | 85.1M | 416M | 412M | 399M | 391M | 456M | 471M | 478M |
| Cash & Short-term Investments | 1.21M | 4.48M | 98.8M | 410M | 330M | 259M | 243M | 293M | 300M | 278M |
| Total Debt | 18.6M | 24.5M | 25.1M | - | 8.20M | 13.4M | 15.3M | 26.3M | 36.9M | 36.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -12.2M | -12.3M | 7.02M | 9.87M | -19.0M | -41.7M | -5.63M | 64.9M | 64.3M | 17.1M |
| Capital Expenditure | 495K | 277K | 937K | 4.75M | 3.48M | 5.63M | 13.6M | 28.3M | 36.0M | 38.1M |
| Free Cash Flow | -12.7M | -12.6M | 6.08M | 5.11M | -22.5M | -47.3M | -19.2M | 36.5M | 28.3M | -21.0M |
| Ratios | ||||||||||
| ROE | - | - | 6.2% | -2.5% | -7.6% | -16.8% | -14.7% | 4.0% | -5.1% | -5.8% |
| ROA | -126.0% | -28.4% | 4.4% | -2.3% | -6.8% | -15.0% | -12.7% | 3.4% | -4.2% | -4.8% |
| Net Profit Margin | -89.9% | -27.9% | 10.2% | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% | -7.1% |
| Debt to Equity | - | - | 0.30x | - | 0.02x | 0.03x | 0.04x | 0.06x | 0.08x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Castle Biosciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 1.69M | 0.06 | - |
| 2021 | USD 3.12M | 0.12 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Castle Biosciences Inc
- Insiders 2.28%
- Institutions 87.64%
- Public & others 10.09%
- Shares outstanding 30.8M
- Free float 27.5M
Top funds holding CSTL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Strategic Advisers U.S. Total Stock | 886K | 2.88% | +11.71% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 866K | 2.81% | +1.62% | Sep 2026 |
| iShares Russell 2000 ETF | 755K | 2.45% | 0.00% | Oct 2026 |
| Principal SmallCap R5 | 577K | 1.87% | -2.37% | Sep 2026 |
| Fidelity Small Cap Index | 328K | 1.06% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 283K | 0.92% | 0.00% | Oct 2026 |
| Wasatch Micro Cap | 277K | 0.90% | 0.00% | Sep 2026 |
| Canada Life US Small-Mid Cap Growth F | 257K | 0.83% | -24.32% | Aug 2026 |
| Buffalo Small Cap Growth | 240K | 0.78% | 0.00% | Jun 2026 |
| iShares Biotechnology ETF | 234K | 0.76% | -0.19% | Oct 2026 |
| Vanguard Explorer Inv | 228K | 0.74% | -17.33% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 201K | 0.65% | +5.63% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 178K | 0.58% | +0.27% | Oct 2026 |
| Vanguard Russell 2000 ETF | 174K | 0.56% | +1.16% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 163K | 0.53% | +0.24% | Oct 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 153K | 0.50% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 142K | 0.46% | -5.30% | Sep 2026 |
| DFA U.S. Small Cap I | 135K | 0.44% | 0.00% | Sep 2026 |
| Advisors Capital Small/Mid Cap | 135K | 0.44% | 0.00% | Jun 2026 |
| Nuveen Quant Small Cap Equity R6 | 131K | 0.43% | 0.00% | Aug 2026 |
Top institutions holding CSTL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 3.29M | 10.78% | +10.36% | Jun 2026 |
| RTW INVESTMENTS, LLC | 2.78M | 9.09% | +0.73% | Jun 2026 |
| Principal Financial Group Inc | 1.50M | 4.91% | -13.07% | Sep 2026 |
| Vanguard Capital Management, LLC | 1.23M | 4.01% | +4.16% | Jun 2026 |
| Acadian Asset Management LLC | 919K | 3.01% | +89.63% | Jun 2026 |
| Allianz Asset Management AG | 879K | 2.88% | +8.37% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 841K | 2.75% | -2.44% | Jun 2026 |
| Summit Partners Public Asset Management, LLC | 825K | 2.70% | -12.31% | Jun 2026 |
| State Street Corp | 822K | 2.69% | +6.89% | Jun 2026 |
| Geode Capital Management, LLC | 796K | 2.61% | +9.31% | Jun 2026 |
| Mackenzie Investments | 794K | 2.60% | +970.70% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 692K | 2.27% | -12.51% | Sep 2026 |
| Jefferies Financial Group Inc | 647K | 2.12% | 0.00% | Jun 2026 |
| Qube Research & Technologies | 589K | 1.93% | +5.31% | Jun 2026 |
| AIGH Capital Management, LLC | 545K | 1.78% | -7.70% | Jun 2026 |
| Renaissance Technologies Corp | 371K | 1.22% | -30.33% | Jun 2026 |
| The Goldman Sachs Group Inc | 358K | 1.17% | +5.05% | Jun 2026 |
| Point72 Asset Management, L.P. | 357K | 1.17% | 0.00% | Jun 2026 |
| Kennedy Capital Management Inc | 348K | 1.14% | 0.00% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 332K | 1.09% | -12.03% | Jun 2026 |
Castle Biosciences Inc company profile
- Company name
- Castle Biosciences Inc
- Ticker
- CSTL.US
- Exchange
- USA Stocks
- Listed since
- Jul 25, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,048
- Fiscal year end
- December
- Address
- 1500 W. Parkwood Ave, Friendswood, TX, United States, 77546
- Phone
- 866 788 9007
- Website
- castlebiosciences.com
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences Inc management
10- Mr. Derek J. MaetzoldFounder, CEO, President & Director · born 1962
- Mr. Frank StokesCFO & Treasurer · born 1970
- Ms. Kristen M. Oelschlager R.N.Chief Operating Officer · born 1969
- Mr. Tobin W. JuvenalChief Commercial Officer · born 1961
- Ms. Camilla ZuckeroVice President of Investor Relations & Corporate Affairs
- Mr. Kevin DomanSenior Vice President of Sales
- Dr. Jay Braxton Pharm.D.Senior Vice President of Marketing
- Ms. Keli GreenbergVice President of Human Resources
- Dr. Matthew Goldberg M.D.Senior Vice President of Medical
- Ms. Trisha PoteetSenior VP of Clinical Services & Manufacturing Operations